<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04326894</url>
  </required_header>
  <id_info>
    <org_study_id>alexmed1391963211966</org_study_id>
    <nct_id>NCT04326894</nct_id>
  </id_info>
  <brief_title>Methorexate and Knee Osteoarthritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alexandria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alexandria</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoarthritis (OA) is considered a complex, multifactorial disease leading to considerable
      pain and functional disability amongst older adults in particular.Synovial inflammation and
      proliferation has emerged as a key component of OA and as a potential predictor of worsening
      disease. Methotrexate (MTX) is widely used in the treatment of all inflammatory rheumatic
      diseases. Accordingly, the aim of the present study is to assess the efficacy of methotrexate
      (MTX) in decreasing pain and inflammation in symptomatic knee OA.

      128 patients with clinical and radiographic criteria of primary knee OA pain,were recruited.
      Patients meeting the eligibility criteria are randomized in a 1:1 ratio to receive either
      25mg/week oral MTX (n=64) or placebo (n=64) together with their usual therapy provided the
      dosages are kept constant for 32 weeks. The primary outcome measure is pain reduction and
      secondary outcome measures is improvement in physical function scores.

      Keywords:

      methotrexate knee osteoarthritis inflammation pain reduction physical funtion
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain reduction</measure>
    <time_frame>8 months</time_frame>
    <description>The primary outcome measure was pain reduction.Pain was assessed using the Visual Analogue pain Scale, (VAS, 0-100 mm).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical function improvement</measure>
    <time_frame>8 months</time_frame>
    <description>Functional assessment was performed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Activities of daily living (ADL) scores.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Pain Reduction</condition>
  <condition>Physical Function Improvement</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25mg oral MTX tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>25 mg/week placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25 mg/week oral methotrexate tablets</intervention_name>
    <arm_group_label>Methotrexate</arm_group_label>
    <other_name>interventional drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25mg/week oral placebo tablets</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary knee osteoarthritis

          -  synovitis

          -  pain

        Exclusion Criteria:

          -  other inflammatory conditions

          -  hepatic insufficiency

          -  renal insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Alexandria</city>
        <zip>00203</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 8, 2013</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alexandria</investigator_affiliation>
    <investigator_full_name>Anna Abou-Raya</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>methotrxate, knee osteoarthritis, inflammation, pain, function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

